Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS

NCT01731925 is registered in ClinicalTrials.gov with GERCOR - Multidisciplinary Oncology Cooperative Group as lead sponsor.

NCT NCT01731925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01731925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Phase 2
Overall status
Unknown status
Start date
January 7, 2013
Completion date
December 31, 2017
Enrollment
44 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid tumors